CHARACTERISTICS OF THE HEMOSTASIS MECHANISM IN PATIENTS WITH SARS-CoV-2 VIRAL INFECTION
Hemostasis in SARS-CoV-2 infection
Abstract
Introduction: During the SARS-CoV-2 pandemic, there has been a significant number of cases accompanied by thrombosis. The precise pathophysiological mechanism remains unclear. The importance of the fibrinolytic mechanism in maintaining physiological hemostasis led us to explore its potential contribution to COVID-19-induced thromboembolism. This study aimed to identify changes in the hemostasis at the time of admission of SARS-CoV-2-positive patients to the hospital and their influence on the disease outcome.
Methods: The presented prospective study includes 60, rt-PCR-confirmed, patients hospitalized in the Covid units of the Clinical Center of Vojvodina. Platelet number, platelet aggregability, aPTT, PT, fibrinogen, D-dimer, and ECLT were determined from blood samples. Participants were classified as those with preserved and suppressed primary hemostasis, those with physiological and increased thrombin activity, those with preserved and decreased fibrinolytic activity, and those with positive and negative disease outcomes.
Results: 44 positive outcomes were observed (73.3%), while a negative outcome, including thromboembolic complications and death, was present in 16 subjects (26.7%). Unconditional logistic regression revealed a mild negative influence of all investigated parameters on the disease outcome. For ECLT OR was 1.084 with 95%CI 1.023-1.160. The multivariate regression model showed that of all investigated parameters, only ECLT was a significant predictor for negative outcome with a level of p<0.001.
Conclusion: The global assessment of the fibrinolytic mechanism is a useful predictor of disease outcome in SARS-CoV-2-positive patients at the moment of their admission to hospital treatment.
Keywords: SARS-CoV-2, Covid-19, hemostasis, fibrinolysis
References
2. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet. 2020; 8(6):e46–7.
3. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S. Effect of Plasminogen Activator (Urokinase), Plasmin, and Thrombin on Glycoprotein and Collagenous Components of Basement Membrane. Cancer Res. 1981;41(11): 4629-4636.
4. Esmon CT. Inflammation and the Activated Protein C Anticoagulant Pathway. Semin Thromb Hemost. 2006; 32(1):49–60.
5. Weiler H. Regulation of inflammation by the protein C system. Crit Care Med. 2010;38:18-25
6. Medcalf RL, Keragala CB. Fibrinolysis: A Primordial System Linked to the Immune Response. Int J Mol Sci. 2021;22(7):3406.
7. Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19. Ann Intern Med. 2020;173(4):268–77.
8. Edler C, Schröder AS, Aepfelbacher M, Fitzek A, Heinemann A, Heinrich F, et al. Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive 80 cases in Hamburg, Germany. Int J Leg Med. 2020;134(4):1275–84.
9. Elsoukkary SS, Mostyka M, Dillard A, Berman DR, Ma LX, Chadburn A, et al. Autopsy Findings in 32 Patients with COVID-19: A Single-Institution Experience. Pathobiology. 2021;88(1):56–68.
10. Heinz C, Miesbach W, Herrmann E, Sonntagbauer M, Raimann FJ, Zacharowski K, et al. Greater Fibrinolysis Resistance but No Greater Platelet Aggregation in Critically Ill COVID-19 Patients. Anesthesiology. 2021;134(3):457–67.
11. di Micco P, Russo V, Carannante N, Imparato M, Cardillo G, Lodigiani C. Prognostic Value of Fibrinogen among COVID-19 Patients Admitted to an Emergency Department: An Italian Cohort Study. J Clin Med. 2020;9(12):4134.
12. Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020;18(6):1324–9.
13. Naymagon L, Zubizarreta N, Feld J, van Gerwen M, Alsen M, Thibaud S, et al. Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19. Thromb Res. 2020;196:99–105.
14. Wright FL, Vogler TO, Moore EE, Moore HB, Wohlauer M v., Urban S, et al. Fibrinolysis Shutdown Correlation with Thromboembolic Events in Severe COVID-19 Infection. J Am Coll Surg. 2020;231(2):193-203.
15. Bachler M, Bösch J, Stürzel DP, Hell T, Giebl A, Ströhle M, et al. Impaired fibrinolysis in critically ill COVID-19 patients. Br J Anaesth. 2021;126(3):590–8.
16. Blasi A, von Meijenfeldt FA, Adelmeijer J, Calvo A, Ibañez C, Perdomo J, et al. In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation. J Thromb Haemost. 2020;18(10):2646–53.